Adbry

Indicated For

moderate-to-severe atopic dermatitis

About This Medication

# Adbry Patient Assistance Program Patient Guide: How to Get Adbry (tralokinumab-ldrm) at Low or No Cost Adbry (tralokinumab-ldrm) is an injectable biologic medication approved by the FDA to treat moderate-to-severe atopic dermatitis (eczema) in adults and children 12 years and older whose condition is not well controlled with topical prescription therapies or when those therapies are not advisable. **This guide explains the Adbry Patient Assistance Program (PAP)**, offered by LEO Pharma Inc., which provides **Adbry at no cost** to eligible patients with demonstrated financial need and limited or no prescription coverage.[1][8][10] ## Who Qualifies for the Program? The program is designed for patients facing financial hardship who cannot afford their medication. Key eligibility factors include: - **Income at or below 600% of the Federal Poverty Level (FPL)**. This is a generous threshold, making it accessible to many lower- and middle-income households. Specific household income limits are not fixed dollar amounts in the program details but are calculated based on current FPL guidelines, adjusted annually by the U.S. Department of Health and Human Services. - **Demonstrated financial need**, typically proven through documents like tax returns or pay stubs. - **Limited or no prescription insurance coverage**. This includes uninsured patients, underinsured individuals, and Medicare Part D enrollees (eligible until the end of their coverage year).[10] - A valid prescription for Adbry from your healthcare provider (HCP). **Note**: Enrollment in the broader Adbry Advocate Program is often required for patient assistance benefits, but not for copay support.[1][2] ## About Adbry (tralokinumab-ldrm) Adbry is a monoclonal antibody that targets interleukin-13 (IL-13), a key protein involved in the inflammation causing eczema flare-ups. Administered as a subcutaneous injection (under the skin), it starts with loading doses at weeks 0, 2, and 4, followed by maintenance doses every 2 weeks. It's used for long-term management when other treatments fail. Common side effects include upper respiratory tract infections, conjunctivitis (eye inflammation), and injection site reactions. Always discuss risks and benefits with your doctor. Adbry is part of LEO Pharma's commitment to eczema care through programs like Adbry Advocate, which offers additional support such as injection training and insurance help.[1][2][5] ## Income Eligibility Breakdown Eligibility hinges on household income not exceeding **600% of the FPL**. Use the table below for 2026 estimates (based on 2025 FPL guidelines projected forward; check HHS.gov for exact current figures, as they update yearly for Alaska and Hawaii). | Household Size | 100% FPL (Contiguous U.S.) | 600% FPL Threshold | |----------------|----------------------------|---------------------| | 1 | $15,060 | $90,360 | | 2 | $20,440 | $122,640 | | 3 | $25,820 | $154,920 | | 4 | $31,200 | $187,200 | | +1 per member | +$5,380 | +$32,280 | **Example**: A family of 4 earning $180,000 annually would qualify if below the threshold. Provide recent income proof (e.g., last year's tax return, W-2s, or three months of pay stubs). Program assesses **demonstrated financial need** holistically.[8] ## Insurance Requirements - **Uninsured or underinsured** with limited/no prescription coverage. - **Medicare Part D patients** are eligible until the end of their coverage year. - **Commercial insurance** patients may access related programs like Rapid Access (free first dose) or Bridge Care, but PAP focuses on those without adequate coverage.[2][10] Patients cannot seek reimbursement for free drug received. Do not double-dip with other assistance.[1] ## Step-by-Step Application Process 1. **Discuss with your HCP**: Confirm Adbry is right for you. They complete the **Enrollment and Prescription Form** and **Healthcare Provider eRx Certification** if applicable.[1][10] 2. **Gather documents**: - Patient Consent Form (sign to authorize sharing info with LEO Pharma).[2] - Proof of financial need (tax returns, pay stubs, etc.). - Proof of income and household size.[8] 3. **Submit application** (multiple methods): - **Online**: Visit https://adbryerx.com/#/ for digital enrollment or eRx.[10] - **Phone**: Call (844) 692-3279 (844-MY-ADBRY), Mon-Fri 8 AM–8 PM ET, for help from Adbry Advocate team.[1][2] - **Fax**: HCP faxes form to 855-423-0011.[10] 4. **Program review**: LEO verifies insurance, income, and need. A case manager coordinates.[2] 5. **Approval notification**: You'll be contacted. **Reauthorization is required** annually or as needed.[program data] ## Timeline and Delivery Processing time varies; rapid programs like first-dose delivery aim for 48 hours for commercial patients, but PAP may take longer due to financial review and case manager coordination for patient shipments. Medication ships **free to your home or HCP's office**. A representative handles logistics, which may extend delivery. Track via Advocate support.[1][2] ## Alternatives if Denied - **Appeal**: Contact (844) 692-3279 to discuss reasons (e.g., income slightly over limit) and resubmit docs.[1] - **Copay Savings Card**: For commercial insurance; pay as low as $0/fill (enrollment not always required).[3][9] - **Rapid Access/Bridge Programs**: Free initial doses or coverage delays.[2][6] - **Other PAPs**: Check RxAssist.org or NeedyMeds for generics/biosimilars (none listed for Adbry).[4][8] - **State programs**, manufacturer copay assistance, or 340B clinics. - **Patient Access Network (PAN) Foundation** or similar for eczema. Always consult your HCP for switches. ## Important Disclaimer This guide is for informational purposes based on program details as of 2026 and public sources. **LEO Pharma reserves the right to change, amend, or end the program anytime without notice**. Eligibility not guaranteed; restrictions apply. Not a substitute for professional medical/financial advice. Verify details at https://adbryerx.com or by calling (844) 692-3279. Full terms at Adbry HCP site.[1][5] Word count: 1028.

Program information last verified: March 30, 2026